Health-related quality of life analysis of the LEAP-002 study of lenvatinib plus pembrolizumab versus lenvatinib as first-line treatment for advanced hepatocellular carcinoma
LEAP-002 研究比较乐伐替尼联合帕博利珠单抗与乐伐替尼单药作为晚期肝细胞癌一线治疗方案的健康相关生活质量分析
期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2025.105065
Finn, R S; Kudo, M; Merle, P; Meyer, T; Qin, S; Ikeda, M; Xu, R; Edeline, J; Ryoo, B-Y; Ren, Z; Cheng, A-L; Galle, P R; Kaneko, S; Kumada, H; Kamble, S; Norquist, J M; Mody, K; Wang, A; Dubrovsky, L; Llovet, J M